Last reviewed · How we verify
Wobenzym®
At a glance
| Generic name | Wobenzym® |
|---|---|
| Sponsor | Mucos Pharma GmbH & Co. KG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis (NA)
- Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance (PHASE3)
- Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis (PHASE2, PHASE3)
- Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wobenzym® CI brief — competitive landscape report
- Wobenzym® updates RSS · CI watch RSS
- Mucos Pharma GmbH & Co. KG portfolio CI